Skip to main content
. 2022 Jun 9;107(10):2523–2526. doi: 10.3324/haematol.2022.281398

Figure 2.

Figure 2.

Pre- and post-daratumumab changes in hemoglobin levels, reticulocyte percentage and monoclonal protein studies.

HHS Vulnerability Disclosure